GeneDx Holdings (WGS) Net Equity Issued and Repurchased (2021 - 2026)

GeneDx Holdings (WGS) has reported Net Equity Issued and Repurchased for 4 consecutive years, with $476000.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $476000.0 in Q1 2026; TTM through Jun 2026 was $476000.0, a 99.77% decrease from a year earlier, with the FY2022 full-year figure at $197.7 million, down 43.53% from the prior year.
• Net Equity Issued and Repurchased was $476000.0 for Q1 2026 at GeneDx Holdings, down from $7.6 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $197.7 million in Q4 2022 and troughed at -$197.7 million in Q3 2022.
• A 3-year average of $2.0 million and a median of $4.0 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 156.49% in 2022, down 156.49% in 2022.
• Over 3 years, Net Equity Issued and Repurchased stood at $197.7 million in 2022, then plunged by 96.15% to $7.6 million in 2023, then slumped by 93.74% to $476000.0 in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $476000.0 (Q1 2026), $7.6 million (Q2 2023), and $197.7 million (Q4 2022), per Business Quant data.